CN114766672A - Old lobular broadleaf holly leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury - Google Patents
Old lobular broadleaf holly leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury Download PDFInfo
- Publication number
- CN114766672A CN114766672A CN202210579058.0A CN202210579058A CN114766672A CN 114766672 A CN114766672 A CN 114766672A CN 202210579058 A CN202210579058 A CN 202210579058A CN 114766672 A CN114766672 A CN 114766672A
- Authority
- CN
- China
- Prior art keywords
- old
- extract
- lobular
- broadleaf holly
- leaf extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003332 Ilex aquifolium Nutrition 0.000 title claims abstract description 21
- 235000002296 Ilex sandwicensis Nutrition 0.000 title claims abstract description 21
- 235000002294 Ilex volkensiana Nutrition 0.000 title claims abstract description 21
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 235000013305 food Nutrition 0.000 title claims abstract description 9
- 231100000753 hepatic injury Toxicity 0.000 title abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 4
- 241001122767 Theaceae Species 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000009210 therapy by ultrasound Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 229940092665 tea leaf extract Drugs 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 abstract description 6
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 abstract description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 5
- 229930195725 Mannitol Natural products 0.000 abstract description 5
- YMWRMAOPKNYHMZ-LLVTZOIGSA-N [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 YMWRMAOPKNYHMZ-LLVTZOIGSA-N 0.000 abstract description 5
- RPMNUQRUHXIGHK-PYXJVEIZSA-N apigenin 7-O-neohesperidoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 RPMNUQRUHXIGHK-PYXJVEIZSA-N 0.000 abstract description 5
- 229930034861 apigenin-7-O-neohesperidoside Natural products 0.000 abstract description 5
- 239000000594 mannitol Substances 0.000 abstract description 5
- 235000010355 mannitol Nutrition 0.000 abstract description 5
- YMWRMAOPKNYHMZ-FFPRBYOHSA-N poliumoside Natural products C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO[C@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@@H]4O)[C@H]2OC(=O)C=Cc5ccc(O)c(O)c5)[C@H](O)[C@H](O)[C@H]1O YMWRMAOPKNYHMZ-FFPRBYOHSA-N 0.000 abstract description 5
- RPMNUQRUHXIGHK-SBDOOABHSA-N rhoifolin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C=C(c3ccc(O)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RPMNUQRUHXIGHK-SBDOOABHSA-N 0.000 abstract description 5
- VPAOSFFTKWUGAD-TVKJYDDYSA-N skimmin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=CC(=O)O2)C2=C1 VPAOSFFTKWUGAD-TVKJYDDYSA-N 0.000 abstract description 2
- SBFTZUUHPXPXLH-UHFFFAOYSA-N skimmin Natural products OCC1OC(C(O)C(O)C1O)c2ccc3C=CC(=O)Oc3c2 SBFTZUUHPXPXLH-UHFFFAOYSA-N 0.000 abstract description 2
- VPAOSFFTKWUGAD-UHFFFAOYSA-N umbelliferone beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=CC(=O)O2)C2=C1 VPAOSFFTKWUGAD-UHFFFAOYSA-N 0.000 abstract description 2
- AAWZDTNXLSGCEK-WYWMIBKRSA-N (-)-quinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1O AAWZDTNXLSGCEK-WYWMIBKRSA-N 0.000 abstract 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 abstract 1
- OXHVQSRYUNGYOK-UHFFFAOYSA-N forsythoside E Natural products COc1ccc(CCOC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)cc1O OXHVQSRYUNGYOK-UHFFFAOYSA-N 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 16
- 241000209035 Ilex Species 0.000 description 14
- 230000001476 alcoholic effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 10
- 239000006187 pill Substances 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000035622 drinking Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000008706 Ilex latifolia Nutrition 0.000 description 3
- 244000078118 Ilex latifolia Species 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 coumarin, vitamin Chemical class 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037237 body shape Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MUUDYSFWQUSAOO-UHFFFAOYSA-N cudraflavone C Chemical compound CC(C)=CCC=1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC=1C1=CC=C(O)C=C1O MUUDYSFWQUSAOO-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GWTUHAXUUFROTF-JUHZACGLSA-N 1-O-caffeoylquinic acid Chemical compound [C@H]1(C[C@@](C(=O)O)(C[C@@H](O)[C@@H]1O)OC(=O)/C=C/C1=CC=C(O)C(O)=C1)O GWTUHAXUUFROTF-JUHZACGLSA-N 0.000 description 1
- GWTUHAXUUFROTF-NCZKRNLISA-N 1-O-caffeoylquinic acid Natural products O[C@@H]1C[C@@](C[C@@H](O)[C@@H]1O)(OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GWTUHAXUUFROTF-NCZKRNLISA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- GYFFKZTYYAFCTR-JUHZACGLSA-N 4-O-trans-caffeoylquinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-JUHZACGLSA-N 0.000 description 1
- GYFFKZTYYAFCTR-UHFFFAOYSA-N 5-O-(6'-O-galloyl)-beta-D-glucopyranosylgentisic acid Natural products OC1CC(O)(C(O)=O)CC(O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- ACBOFPQSBWBAQR-UHFFFAOYSA-N Cosmosiin Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(Oc3c2)c4cccc(O)c4)C(O)C(O)C1O ACBOFPQSBWBAQR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- DTOUWTJYUCZJQD-UJERWXFOSA-N Forsythiaside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 DTOUWTJYUCZJQD-UJERWXFOSA-N 0.000 description 1
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 241000735234 Ligustrum Species 0.000 description 1
- 241001108829 Ligustrum quihoui Species 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- XYXONTIQGZKCNH-UYKXVWJOSA-N Lonicerin Natural products CO[C@@H]1O[C@@H](O)[C@H]([C@H]2C[C@H](O)[C@H](C)[C@@H]12)C(=O)OC XYXONTIQGZKCNH-UYKXVWJOSA-N 0.000 description 1
- UWQYBLOHTQWSQD-UHFFFAOYSA-N Mulberrin Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2CC=C(C)C)=O)=C1OC=2C1=CC=C(O)C=C1O UWQYBLOHTQWSQD-UHFFFAOYSA-N 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- SHPPXMGVUDNKLV-UHFFFAOYSA-N Veronicastroside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- IYKFYARMMIESOX-UHFFFAOYSA-N adamantanone Chemical compound C1C(C2)CC3CC1C(=O)C2C3 IYKFYARMMIESOX-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- KMOUJOKENFFTPU-JOZSIVFUSA-N apigenin-7-O-beta-D-glucopyranoside Natural products OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)-c2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O KMOUJOKENFFTPU-JOZSIVFUSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- GYFFKZTYYAFCTR-LMRQPLJMSA-N cryptochlorogenic acid Natural products O[C@H]1C[C@@](O)(C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-LMRQPLJMSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- SHPPXMGVUDNKLV-KMFFXDMSSA-N luteolin 7-O-neohesperidoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-KMFFXDMSSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- DUBCCGAQYVUYEU-ZUGPOPFOSA-N miquelianin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O DUBCCGAQYVUYEU-ZUGPOPFOSA-N 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- RTATXGUCZHCSNG-ZFDPGQBLSA-N nicotiflorin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RTATXGUCZHCSNG-ZFDPGQBLSA-N 0.000 description 1
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- DUBCCGAQYVUYEU-GGTBVAQXSA-N quercetin-3-glucuronide Natural products O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O DUBCCGAQYVUYEU-GGTBVAQXSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a small-leaf broadleaf holly leaf old leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury, and relates to the technical field of food processing. The preparation process of the old lobular broadleaf holly leaf extract comprises the steps of raw material pretreatment, crushing, extraction, concentration, drying, crushing and the like. The prepared old lobular broadleaf holly leaf extract is rich in 54 effective components such as verbascoside, poliumoside, mannitol, rhoifolin, forsythoside E, D-quinic acid, skimmin and the like, and can be used for preparing functional food for relieving alcohol-induced liver injury.
Description
Technical Field
The invention relates to the technical field of food processing, in particular to a small-leaf broadleaf holly leaf old leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury.
Background
The lobular broadleaf holly leaf is tea processed from fresh leaves of ligustrum quihoui of oleaceae ligustrum, is commonly called as tea leaves, fuding tea and tea-like, and is a traditional pure natural health care beverage good product in China. The finished tea has the advantages of fresh fragrance, bitter taste and sweet and cool taste, and has the effects of clearing away summer heat, improving eyesight, promoting intelligence, promoting the production of body fluid, quenching thirst, promoting urination, strengthening heart, moistening throat, relieving cough, lowering blood pressure, reducing weight, inhibiting and preventing cancers, resisting aging, invigorating blood circulation and the like. From the perspective of traditional Chinese medicine, the broadleaf holly leaf tea has the effects of dispelling wind heat, clearing head and eyes and removing polydipsia, and has very obvious medicinal effects of treating headache, toothache, conjunctival congestion, fever polydipsia, dysentery and the like.
Disclosure of Invention
The invention discloses a method for extracting an old lobular ilex leaf extract by crushing, extracting, concentrating, drying and crushing, measuring the content of the extract by HPLC, and analyzing the content to obtain the extract containing verbascoside, poliumoside, mannitol, rhoifolin, forsythiaside E, dextroquinic acid, skimmin, apigenin-7-O-beta-D-glucopyranoside, oleuropein, luteolin, rutin, salidroside, adenine, citric acid, 5-hydroxyverbascoside, violaxoside C, lonicerin, p-hydroxycinnamic acid, quercetin-3-glucuronide, coumarin, vitamin II, hyperin, L-leucine, mulberrin, L-phenylalanine, mogroside, akebiaquine B, atractyloide A, p-methoxybenzaldehyde, L-tyrosine, D-beta-D-E, Apigenin, hydroxytyrosol, kaempferol-3-O-rutinoside, plantain, bilobalide, guanine, 2-adamantanone, dencichine, protocatechualdehyde, luteolin, protocatechuic acid, camphor, cryptochlorogenic acid, shikimic acid, caffeic acid, 1-caffeoylquinic acid, verbascoside, phillyrin, loganin, 6-gingerol, danshensu, vanillin, and acetyl harpagin. The preparation process of the old lobular broadleaf holly leaf extract comprises the following steps:
(1) pretreatment of raw materials: carrying out steam de-enzyming and drying treatment on fresh and complete lobular Kuding tea to obtain old lobular Kuding tea leaves;
(2) crushing: crushing the old lobular Kuding tea leaves by a crusher and sieving by a sieve of 10 meshes;
(3) extraction: weighing the crushed raw materials, putting the raw materials into a filter bag, adding water, adding distilled water, uniformly mixing, soaking at normal temperature, heating the raw materials, keeping the temperature, performing ultrasonic treatment on the raw materials after stopping heating, performing suction filtration after treatment, repeatedly extracting filter residues for 2-3 times, and combining filtrates;
(4) concentration: carrying out rotary evaporation and concentration on the filtrate until the filtrate is sticky and is taken out;
(5) and (3) drying: pre-freezing the concentrated solution, and freeze-drying to obtain solid concentrated extract;
(6) crushing: pulverizing the solid concentrated extract, and sieving with 300 mesh sieve to obtain small leaf Folum Ilicis old leaf extract.
Further, the ratio of the tea leaves to the water in the step (3) is 1 g: 10-20 mL.
Further, the soaking time at normal temperature in the step (3) is 3-5 h.
Further, the raw materials in the step (3) are heated at 90-95 ℃, the heat preservation time is 1-2 hours, and in the heat preservation process, stirring is carried out for 5min every 15 min.
Further, in the step (3), the ultrasonic treatment frequency is 30-40 KHZ, and the ultrasonic treatment time is 10-20 min.
Further, the concentration temperature in the step (4) is 50-70 ℃.
Further, the moisture content of the solid concentrated extract in the step (5) is less than 6%.
The invention also provides the old lobular broadleaf holly leaf extract prepared by the method.
The invention also aims to provide application of the old lobular Kuding tea leaf extract in preparing food for relieving alcohol-induced liver injury.
The main components of the old lobular broadleaf holly leaf extract comprise verbascoside, poliumoside, mannitol, rhoifolin and the like, and the specific effects of the components are as follows:
poliumoside: removing blood stasis, stopping bleeding, relieving swelling and pain, and can be used for hematemesis, hemoptysis, epistaxis, and hematochezia; the external use has the functions of treating traumatic hemorrhage, resisting bacteria, diminishing inflammation and resisting viruses; verbascoside: has antiinflammatory, immunity enhancing, anoxia resisting, and anticancer effects, can be used for content determination/identification/pharmacological experiment, and has pharmacological effects of regulating immunity, resisting oxidation, enhancing physical strength, relieving fatigue, etc.; rhoifolin: anti-tumor; anti-hypertension; xanthine oxidase inhibitors; an antioxidant; mannitol: is a good diuretic in medicine, reduces intracranial pressure and intraocular pressure, and is a drug for treating kidney, dehydrate, sugar substitute, excipient for tablet, and diluent for solid and liquid.
Compared with the prior art, the invention has the following beneficial technical effects:
the extract of the old leaves of the ilex latifolia is rich in functional components such as verbascoside, poliumoside, mannitol, isoergosterol, rhoifolin and the like, can be directly drunk after being dissolved in water or prepared into functional beverage with other components for drinking, can relieve alcoholic liver injury caused by long-term drinking after long-term drinking, and has the effects of resisting bacteria, diminishing inflammation, enhancing immunity, resisting oxidation, enhancing physical strength, resisting fatigue, promoting urination and the like. Meanwhile, the material source of the invention is wide, the cost is low, the preparation process is simple, and the invention has good application prospect.
Drawings
The invention is further illustrated in the following description with reference to the drawings.
FIG. 1 is a graph of the effect on liver in mice with alcoholic liver injury at 4 weeks of administration;
FIG. 2 is a graph showing the changes in serum ALT and AST levels after 4 weeks of administration;
FIG. 3 is a graph showing the change in the amount of TG in serum after 4 weeks of administration.
Detailed Description
The technical solution provided by the present invention is further illustrated by the following examples.
Example 1
A preparation process of an old lobular broadleaf holly leaf extract comprises the following steps:
(1) pretreatment of raw materials: carrying out steam de-enzyming and drying treatment on fresh and complete lobular Kuding tea to obtain old lobular Kuding tea leaves;
(2) crushing: crushing the old lobular Kuding tea leaves by a crusher and sieving the crushed old lobular Kuding tea leaves by a sieve with 10 meshes;
(3) extraction: weighing the crushed raw materials, putting the raw materials into a filter bag, and mixing the raw materials according to a material-liquid ratio of 1 g: adding 20mL of water into distilled water, mixing, soaking at room temperature for 5h, heating the raw materials to 95 deg.C, keeping the temperature for 2h, heating for 15min, stirring for 5min, stopping heating, performing 40KHZ ultrasonic treatment for 15min, pouring out the extractive solution, vacuum filtering, repeatedly extracting the residue for 3 times, and mixing the filtrates;
(4) and (3) concentrating: heating the extractive solution with 50 deg.C water bath, concentrating with rotary distiller to viscous state, and pouring out;
(5) and (3) drying: storing the concentrated solution at-5 deg.C, freezing and drying to obtain solid concentrated extract;
(6) crushing: pulverizing the solid concentrated extract, and sieving with 300 mesh sieve to obtain folium Ilicis Purpureae old leaf extract.
Test example 1
(1) Experimental materials: 46 SPF male KM mice with the body weight of 20-25 g are 4-6 weeks old. The experimental reagent comprises a red star Erguotou (purchased from Dewangjia supermarket of New city of Baiyun area in Guiyang); bifendate dripping pills; 4% paraformaldehyde.
(2) The experimental method comprises the following steps:
alcohol liver injury model making
The 60 mice were randomly divided into two groups, 10 normal groups and 50 model groups. The normal weight group measured every week is subjected to intragastric administration for 1 time per day; the module building set is filled with sterile water for 3 days to adapt to stimulation, and then filled with 56-degree Hongxing Erguotou for 3 weeks: the acute alcoholic liver injury model is established by gavage 1 time daily with 0.005ml/g in the first week, gavage 1 time daily with 0.008ml/g in the second week, and gavage 1 time daily with 0.010ml/g in the third week.
Animal grouping and handling
45 mice remained after modeling, 10 mice remained in the normal group, and 10 mice remained in the modeling group. 36 mice of the modeling group are randomly divided into 4 groups of 9 groups, namely a model group, a positive drug group (bifendate dripping pills), a broadleaf holly leaf extract low-dose group and a broadleaf holly leaf extract high-dose group. The administration group is administered by intragastric administration for 1 time every day, and the blank control group and the model group are administered with equal volume of sterile water every time for continuous intragastric administration. The mice were subjected to eye blood sampling and tissue isolation at 2 and 4 weeks of administration, respectively. The grouping situation is as follows:
table 1: grouping of experimental animals
Group of | Quantity (only) | Concentration of Folum Ilicis extract |
Normal group | 9 | — |
Model set | 9 | — |
Positive drug group | 9 | 150mg/kg |
Low dose group | 9 | 150mg/kg |
High dose group | 9 | 300mg/kg |
Detecting relevant indexes of experimental animals:
1) general observations were: in the experimental process, the mental state, the activity, the fur color, the water intake, the food intake, the urination and defecation condition, the presence or absence of a bite wound, death and other conditions of the experimental mice are observed every day. If mice die, the number of mice die and the possible cause of the death should be recorded.
2) And (3) determination of serum biochemical indexes: in order to avoid the influence of food on the detection result, after the last administration, the blood is taken from the eyeballs of the experimental mice after being fasted overnight (freely drinking water) for 16 hours, and the fur of the mice is prevented from dropping into the blood. Standing at room temperature for natural coagulation, centrifuging at 4000rpm in a centrifuge for 15min, and separating serum. The serum of each mouse is marked respectively and stored in a-80C ultra-low temperature refrigerator for standby. Respectively measuring the content levels of glutamic-oxaloacetic transaminase (AST), glutamic-pyruvic transaminase (ALT) and Triglyceride (TG) in the serum of the experimental mouse.
3) Mouse liver index determination: before the mice were dissected, the body weight of the mice was weighed and recorded. Immediately after blood collection, the abdomen is opened to pick up mouse liver tissues, filter paper is used for lightly wiping the residual blood on the surface, the appearance of the mouse viscera is observed and photographed for storage, immediately after photographing, the mouse viscera is placed in physiological saline at 4 ℃ for rinsing to remove the residual blood, the filter paper is lightly wiped dry, and the wet weight of the mouse liver is weighed and recorded. Mouse liver index was calculated according to the following formula:
the liver index of the mouse is the wet weight of the liver/body weight multiplied by 100%
Collecting mouse organs:
immediately after blood sampling, the abdomen was opened to extract liver tissue from the mice, and the heart, liver, spleen, and lung were additionally taken out, weighed, and recorded.
And (3) data analysis:
statistical software Excel and SPSS23.0 are adopted for analysis, the measured data are expressed by mean plus minus standard deviation (x plus minus s), the numerical value comparison among a plurality of groups is analyzed by one-factor variance, and the difference with P <0.05 has statistical significance.
(3) Results of the experiment
1) Influence of Folum Ilicis extract on body shape and mental status of diabetic mice
In the molding process, the normal control group mice had good mental status, body shape, free movement, bright hair color, normal food intake and drinking, normal urine output, and no injury. 17 mice die in the molding process of the molding mice, wherein 6 mice are dissected to find that liver tissues of the mice are diseased, 2 mice die after being perfused with stomach alcohol, the rest 9 dead mice are emaciated, intestinal flatulence is observed after dissection, and some mice have alcoholic liver injury. When the model is molded for 3 weeks, most mice lose weight.
In the experimental process, the mental state of each alcoholic liver model mouse is worse than that of a normal control group mouse, and the reaction is slightly retarded; the control group was most significant. Along with the increase of the medicine intervention time, the spirit of each dose group of the broadleaf holly leaf extract and the positive medicine group of the alcoholic liver model mouse is slightly better than that of the model group mouse, and padding is relatively clean. 3 days after administration, the buttocks swelling phenomenon appeared in each alcoholic liver model mouse; after 5 days of administration, the positive drug group mice had wounds on 4 buttocks, four mice in the low dose group had wounds on the tail, 1 mouse in the high dose group had wounds, and 1 leg had wounds; after 8 days of administration, these wounds were gradually recovered, but one each died in the high dose group, the low dose group, the positive drug and the model group. After 2 weeks of administration, 4 of the high dose groups had another wound on the buttocks but had not died.
2) Influence of Folum Ilicis extract on body weight and organ weight of mice with alcoholic liver injury
After 2 weeks and 4 weeks of administration, each mouse organ was collected and weighed and recorded. As can be seen from the table, there was no statistical difference in the body weight and the weight of each organ among the groups, indicating that the Yuqing ilex latifolia extract had no significant effect on the body weight and the weight of each organ of the mice with alcoholic liver injury.
Table 2: the weight of mice and the weight of each organ were administered for 2 weeks
Table 3: the weight of mice and the weight of each organ were administered for 4 weeks
Group of | Body weight | Heart of heart | Spleen | Lung (lung) | Kidney (Kidney) |
Normal group | 51.40±1.41 | 0.27±0.06 | 0.15±0.03 | 0.29±0.04 | 0.68±0.04 |
Model set | 48.15±8.95 | 0.23±0.54 | 0.11±0.04 | 0.26±0.04 | 0.54±0.12 |
Low dose group | 48.96±3.96 | 0.25±0.03 | 0.11±0.01 | 0.26±0.04 | 0.58±0.09 |
High dose group | 42.88±3.94 | 0.20±0.01 | 0.20±0.12 | 0.25±0.01 | 0.55±0.04 |
Positive drug group | 45.22±5.39 | 0.24±0.05 | 0.19±0.17 | 0.25±0.01 | 0.54±0.03 |
3) Influence of broadleaf holly leaf extract on appearance of liver of mice with alcoholic liver injury
As shown in FIG. 1, at week 4 of the intragastric administration of ethanol and the concurrent intragastric administration of the positive control drug and the Folum Ilicis extract, the mice were dissected and sampled to observe pathological changes on the liver surface. The observation result is that the surface of the liver of the normal group is dark red and has no white lesion spots; the surface color of the liver of the model group is light pink, and the liver of the model group has more white lesion spots and slight fibrosis; the surface color of liver tissue of the positive medicine group is pink, and no white lesion spots are few; the surface of the liver tissue of the low-dose group is pink, has slight white lesion spots and is not obvious; the surface of the liver tissue of the high-dose group is dark pink, and white lesion spots do not exist.
4) Effect of Folum Ilicis extract on TG, ALT and AST in mice
And (3) performing eyeball blood collection on the mice at 4 weeks of the intragastric alcohol injection and the intragastric positive control drug and the broadleaf holly leaf extract at the same time, and collecting serum to detect the contents of ALT, AST and TG. As can be seen from FIG. 2, after the 4 th week after the gavage, compared with the model group, the ALT and AST contents in the serum all reached a very significant increase (P <0.01) in the model group, bifendate dripping pills, low dose group and high dose group compared with the normal group; compared with the model group, the content of ALT and AST in serum is also extremely lower than that of the model group in the bifendate dripping pills and the high-dose group (P <0.01), and the content of the bifendate dripping pills and the high-dose group does not reach a significant difference (P >0.05) with the model group; and the content of ALT and AST in serum is not significant (P is more than 0.05) between bifendate dripping pills and high-dose groups. The result shows that the high-dose intragastric extract can relieve alcoholic liver injury to a certain extent, and the effect of the extract is not much different from that of the biphenyl dimethylesterate dropping pill which is a common liver-protecting medicine in the market.
As can be seen from fig. 2, after 4 weeks of administration, compared with the normal group, the TG content in the serum of the mice in the model group and the low dose group was significantly higher than that in the normal group (P <0.01), while the TG content in the serum of the mice in the bifendate dripping pill and the high dose group was significantly higher than that in the normal group (P < 0.05); compared with the model group, the content of the bifendate dripping pills and the high-dose group in the serum of the mice is extremely lower than that of the model group (P <0.01), the difference is not significant compared with other groups, and the difference between the bifendate dripping pills and the high-dose group is not significant (P < 0.05). Therefore, the extract can reduce the increase of TG content in blood caused by alcoholic liver injury by intragastric administration, and the effect is not different from bifendate.
The invention is obtained by combining the above steps, and by carrying out intragastric administration on the ilex latifolia thunb extract, a series of results such as detection of relevant indexes of alcoholic liver injury, behavior observation of intragastric administration animals, weight change, anatomical pathology observation and the like prove that the extract can relieve alcoholic liver injury to a certain degree, and provides experimental basis for further developing and protecting liver products.
The principles and embodiments of the present invention have been described herein using specific examples, which are provided only to help understand the method and the core concept of the present invention; meanwhile, for a person skilled in the art, according to the idea of the present invention, the specific embodiments and the application range may be changed. In view of the above, the present disclosure should not be construed as limiting the invention.
Claims (9)
1. A preparation process of an old leaflet extract of lobular broadleaf holly leaf is characterized by comprising the following steps:
(1) pretreatment of raw materials: carrying out steam de-enzyming and drying treatment on fresh and complete lobular Kuding tea to obtain old lobular Kuding tea leaves;
(2) crushing: crushing the old lobular Kuding tea leaves by a crusher and sieving by a sieve of 10 meshes;
(3) extraction: weighing the crushed raw materials, putting the raw materials into a filter bag, adding water, adding distilled water, uniformly mixing, soaking at normal temperature, heating the raw materials, keeping the temperature, performing ultrasonic treatment on the raw materials after stopping heating, performing suction filtration after treatment, repeatedly extracting filter residues for 2-3 times, and combining filtrates;
(4) and (3) concentrating: carrying out rotary evaporation and concentration on the filtrate until the filtrate is sticky and is taken out;
(5) and (3) drying: pre-freezing the concentrated solution, and freeze-drying to obtain solid concentrated extract;
(6) crushing: pulverizing the solid concentrated extract, and sieving with 300 mesh sieve to obtain folium Ilicis Purpureae old leaf extract.
2. The process for preparing the old small-leaf broadleaf holly leaf extract according to claim 1, wherein the ratio of tea leaves to water in the step (3) is 1 g: 10-20 mL.
3. The process for preparing the old lobular Kuding tea leaf extract according to claim 1, wherein the soaking time in step (3) at normal temperature is 3-5 h.
4. The preparation process of the old small-leaf broadleaf holly leaf extract as claimed in claim 1, wherein the raw material in the step (3) is heated at 90-95 ℃ for 1-2 h, and is stirred for 5min every 15min during the heat preservation process.
5. The process for preparing the old leaflet extract of broadleaf holly leaf according to claim 1, wherein the ultrasonic treatment frequency in the step (3) is 30-40 KHZ, and the ultrasonic treatment time is 10-20 min.
6. The process for preparing the old leaflet extract of lobular Kuding tea as claimed in claim 1, wherein the concentration temperature in the step (4) is 50-70 ℃.
7. The process according to claim 1, wherein the water content of the solid concentrated extract in step (5) is less than 6%.
8. An extract from old leaves of Folum Ilicis, prepared by the method of any one of claims 1-7.
9. The old leaflet extract of lobular Kuding tea as claimed in claim 9, which is used for preparing food for alleviating alcohol-induced liver damage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210579058.0A CN114766672A (en) | 2022-05-25 | 2022-05-25 | Old lobular broadleaf holly leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210579058.0A CN114766672A (en) | 2022-05-25 | 2022-05-25 | Old lobular broadleaf holly leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114766672A true CN114766672A (en) | 2022-07-22 |
Family
ID=82408236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210579058.0A Pending CN114766672A (en) | 2022-05-25 | 2022-05-25 | Old lobular broadleaf holly leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114766672A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115364144A (en) * | 2022-10-07 | 2022-11-22 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Yuqing lobular Kuding tea extract and preparation method and application thereof |
CN115414331A (en) * | 2022-10-12 | 2022-12-02 | 广东彼迪药业有限公司 | Colchicine tablet |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101254222A (en) * | 2007-03-02 | 2008-09-03 | 重生源生物科技(深圳)有限公司 | Applications of lectuce tea total glycosides and method of preparing the same |
CN101449717A (en) * | 2007-11-30 | 2009-06-10 | 张大卫 | Manufacturing method of Lactuca taiwaniana Maxim. plant beverage |
CN101966210A (en) * | 2010-08-09 | 2011-02-09 | 深圳市华熙生物科技有限公司 | Folium llicis latifoliae total glycoside and preparation method thereof |
CN109007152A (en) * | 2018-07-25 | 2018-12-18 | 兴义市绿缘中药材种植农民专业合作社 | A kind of processing method of leaflet Kuding tea bag |
CN110742915A (en) * | 2019-11-06 | 2020-02-04 | 湖北中医药大学 | Application of broadleaf holly leaf aqueous extract and pharmaceutical composition for regulating intestinal micro-ecology |
CN113455572A (en) * | 2021-08-04 | 2021-10-01 | 中国科学院过程工程研究所 | Instant tea of forsythia suspense leaves and preparation method and application thereof |
CN113768151A (en) * | 2021-08-31 | 2021-12-10 | 海南师范大学 | Preparation method and detection method of tea polyphenol in Baisha green tea |
-
2022
- 2022-05-25 CN CN202210579058.0A patent/CN114766672A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101254222A (en) * | 2007-03-02 | 2008-09-03 | 重生源生物科技(深圳)有限公司 | Applications of lectuce tea total glycosides and method of preparing the same |
CN101449717A (en) * | 2007-11-30 | 2009-06-10 | 张大卫 | Manufacturing method of Lactuca taiwaniana Maxim. plant beverage |
CN101966210A (en) * | 2010-08-09 | 2011-02-09 | 深圳市华熙生物科技有限公司 | Folium llicis latifoliae total glycoside and preparation method thereof |
CN109007152A (en) * | 2018-07-25 | 2018-12-18 | 兴义市绿缘中药材种植农民专业合作社 | A kind of processing method of leaflet Kuding tea bag |
CN110742915A (en) * | 2019-11-06 | 2020-02-04 | 湖北中医药大学 | Application of broadleaf holly leaf aqueous extract and pharmaceutical composition for regulating intestinal micro-ecology |
CN113455572A (en) * | 2021-08-04 | 2021-10-01 | 中国科学院过程工程研究所 | Instant tea of forsythia suspense leaves and preparation method and application thereof |
CN113768151A (en) * | 2021-08-31 | 2021-12-10 | 海南师范大学 | Preparation method and detection method of tea polyphenol in Baisha green tea |
Non-Patent Citations (3)
Title |
---|
杨柳;王文地;马允;王文全;侯俊玲;崔洁;: "急性酒精性肝损伤模型的考察及验证", 西北药学杂志, vol. 35, no. 03, pages 391 - 396 * |
潘妍霓;赵欣;龙兴瑶;周先容;母健菲;刘必慧;: "大叶苦丁茶多酚对四氯化碳致小鼠肝损伤的预防作用", 食品工业科技, vol. 40, no. 09, pages 287 - 294 * |
石敏娟等: "苦丁对酒精性脂肪肝大鼠的保护作用及机制研究", 现代中医药, vol. 39, no. 4, pages 134 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115364144A (en) * | 2022-10-07 | 2022-11-22 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Yuqing lobular Kuding tea extract and preparation method and application thereof |
CN115414331A (en) * | 2022-10-12 | 2022-12-02 | 广东彼迪药业有限公司 | Colchicine tablet |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114766672A (en) | Old lobular broadleaf holly leaf extract and application thereof in preparing food for relieving alcohol-induced liver injury | |
KR100956278B1 (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
CN102204678B (en) | Instant cubilose powder with efficacy of immunity enhancement and preparation method thereof | |
CN107397208B (en) | Functional food containing fish glue as main component and its use | |
CN103893252A (en) | Composition capable of clearing heat from throat and relieving sore throat and preparation method and application thereof | |
KR20020041639A (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
KR100699790B1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a Lonicera caerulea L. var. edulis extract | |
CN109601795A (en) | Using penthorum chinense pursh as composition alcohol-decomposing beverage of primary raw material and preparation method thereof | |
CN107279446A (en) | A kind of betel nut colloid chews piece | |
CN111329981B (en) | Antibacterial, anti-inflammatory and blood circulation-promoting microcapsule Chinese herbal medicine composition and preparation method thereof | |
TWI763970B (en) | Carob fruit composition and preparation method and application thereof | |
CN103749824A (en) | Gynostemma pentaphyllum health-care tea capable of lowering blood sugar and blood pressure and preparation method thereof | |
CN104489847A (en) | Solid granular beverage and preparation method thereof | |
CN113288937B (en) | Anti-inflammatory traditional Chinese medicine compound and preparation method and application thereof | |
JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
KR102157048B1 (en) | Composition for preventing or improving non-alcoholic fatty liver disease comprising complex extracts of ginger, centella asiatica and ramie leaf | |
CN106924448B (en) | Pharmaceutical composition for treating wind-heat type common cold and preparation method thereof | |
CN100333767C (en) | Medicine for treating male infertility | |
CN108992559A (en) | For preventing and treating the veterinary Chinese medicinal composition and preparation method thereof of anemopyretic cold and viral influenza | |
CN112274588B (en) | Preparation method and application of extract of plant of genus Convolvulus | |
CN114931214B (en) | Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof | |
CN106727943A (en) | One kind treats phthisical pharmaceutical composition and preparation method thereof | |
CN104474261A (en) | Traditional Chinese medicine wine with effects of securing essence and maintaining health and preparation method thereof | |
CN105560694A (en) | Medicine composition for treating diabetic nephropathy and preparation method thereof | |
CN117298217A (en) | Instant ginseng without excessive internal heat and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |